CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $813,606, lower than 95% of all stocks globally
- PositionOperating margin is -33300%, lower than 95% of its Biotechnology peers (median -38%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
51.77BJPY329.10M · vs all stocks (USD)
Revenue (TTM)
128.00MJPY813.61K · vs all stocks (USD)
Beta
0.8810xvs all stocks
52-Week Change
-19.17%vs all stocks
Market Capitalization
51.77BJPY329.10M · vs all stocks (USD)
Enterprise Value
44.75BJPY284.47M · vs all stocks (USD)
Price to Book (MRQ)
10.82xvs Biotechnology peers
Enterprise to Revenue
349.64xvs Biotechnology peers
Enterprise to EBITDA
-39.53xvs Biotechnology peers
Return on Assets (TTM)
-14.41%vs Biotechnology peers
Return on Equity (TTM)
-23.28%vs Biotechnology peers
Revenue (TTM)
128.00MJPY813.61K · vs all stocks (USD)
Revenue per Share (TTM)
15.53JPYUpdated Sep 21, 2026Quarterly Revenue Growth
-98.80%vs Biotechnology peers
Gross Profit (TTM)
100.00MJPY635.63K · vs all stocks (USD)
EBITDA (TTM)
-1.13BJPY-7.20M · vs all stocks (USD)
Net Income (TTM)
-1.14BJPY-7.24M · vs all stocks (USD)
Operating Cash Flow (TTM)
-1.06BJPY-6.74M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.02BJPY-6.50M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00JPYUpdated Sep 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
18.89MJPYFY2026 · Mar 31, 2026Revenue
212.33MJPYFY2026 · Mar 31, 2026Cost of Goods Sold
81.98MJPYFY2026 · Mar 31, 2026Gross Profit
130.35MJPYFY2026 · Mar 31, 2026Operating Income
-1.08BJPY-6.87M · vs all stocks (USD)
Pre-tax Income
-1.03BJPYFY2026 · Mar 31, 2026Income Tax Expense
3.79MJPYFY2026 · Mar 31, 2026Net Income
-1.03BJPYFY2026 · Mar 31, 2026EBIT
-1.08BJPYFY2026 · Mar 31, 2026EBITDA (Income Statement)
-1.02BJPYFY2026 · Mar 31, 2026Non-operating Interest Income
13.39MJPYFY2026 · Mar 31, 2026Minority Interests (P&L)
7.84MJPYFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00JPYFY2026 · Mar 31, 2026Operating Cash Flow
-751.65MJPYFY2026 · Mar 31, 2026Free Cash Flow
-794.65MJPYFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
3.90BJPYFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-1.03BJPYFY2026 · Mar 31, 2026Stock-based Compensation
62.87MJPYFY2026 · Mar 31, 2026Other Non-cash Items
-5.74MJPYFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
239.95MJPYFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-22.02MJPYFY2026 · Mar 31, 2026Capital Expenditures
-43.01MJPYFY2026 · Mar 31, 2026Net Intangibles (CF)
-6.77MJPYFY2026 · Mar 31, 2026Other Investing Activity
14.82MJPYFY2026 · Mar 31, 2026Net Investing Cash Flow
-28.19MJPYFY2026 · Mar 31, 2026Common Stock Repurchase
-260.00KJPYFY2026 · Mar 31, 2026Other Financing Charges
27.36MJPYFY2026 · Mar 31, 2026Net Financing Cash Flow
204.21MJPYFY2026 · Mar 31, 2026Shares Outstanding
8.26MSharesUpdated Sep 21, 2026Float Shares
5.92MSharesUpdated Sep 21, 2026% Held by Insiders
25.68%vs all stocks
% Held by Institutions
1.23%vs all stocks
Total Cash (MRQ)
3.32BJPY21.12M · vs all stocks (USD)
Total Cash per Share (MRQ)
402.28JPYUpdated Sep 21, 2026Total Debt (MRQ)
0.00JPYvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
16.31xvs Biotechnology peers
Book Value per Share (MRQ)
537.67JPYUpdated Sep 21, 2026Total Assets
5.12BJPY32.56M · vs all stocks (USD)
Total Current Assets
4.42BJPYFY2026 · Mar 31, 2026Total Liabilities
353.83MJPYFY2026 · Mar 31, 2026Total Non-current Assets
702.33MJPYFY2026 · Mar 31, 2026Total Non-current Liabilities
76.31MJPYFY2026 · Mar 31, 2026Total Current Liabilities
277.52MJPYFY2026 · Mar 31, 2026Cash & Cash Equivalents
3.65BJPYFY2026 · Mar 31, 2026Other Short-term Investments
246.58MJPYFY2026 · Mar 31, 2026Accounts Receivable
55.00KJPYFY2026 · Mar 31, 2026Inventory
64.63MJPYFY2026 · Mar 31, 2026Accounts Payable
242.23MJPYFY2026 · Mar 31, 2026Other Current Liabilities
8.71MJPYFY2026 · Mar 31, 2026Other Non-current Liabilities
42.22MJPYFY2026 · Mar 31, 2026Common Stock (Book)
1.77BJPYFY2026 · Mar 31, 2026Retained Earnings
-3.77BJPYFY2026 · Mar 31, 2026Total Shareholders' Equity
4.77BJPY30.32M · vs all stocks (USD)
Treasury Stock
12.85MJPYFY2026 · Mar 31, 202652-Week Low
3.61KJPYUpdated Sep 21, 202652-Week High
12.40KJPYUpdated Sep 21, 202652-Week Change
-19.17%vs all stocks
Beta
0.8810xvs all stocks
50-Day MA
5.08KJPYUpdated Sep 21, 2026200-Day MA
6.13KJPYUpdated Sep 21, 2026Avg 10-Day Volume
77.41KSharesUpdated Sep 21, 2026Avg 30-Day Volume
101.35KSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-124.55JPYUpdated Sep 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -33300%, lower than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: -333Industry median: -0.38Industry P5: -43.63Peers compared: 260
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 1.09
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $813,606, lower than 95% of all stocks globallySignificant
Revenue (USD): 813,606.4Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Hubei Guangji Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Newron Pharmaceuticals SpA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Il Dong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Benitec Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
BioAge Labs, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Golden Throat Holdings Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Lingda Group Co., Ltd.
2 interpretationsLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Xinjiang Machinery Research Institute Co., Ltd.
2 interpretationsLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets